Status:
ENROLLING_BY_INVITATION
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Lead Sponsor:
CRISPR Therapeutics AG
Conditions:
Hematologic Malignancy
Solid Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
Detailed Description
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term fo...
Eligibility Criteria
Inclusion
- Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.
- Must have received CRISPR CAR T cellular therapy.
Exclusion
- There are no specific exclusion criteria.
Key Trial Info
Start Date :
November 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2038
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06208878
Start Date
November 22 2023
End Date
August 1 2038
Last Update
August 14 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope
Duarte, California, United States, 91010
2
Cedars Sinai
Los Angeles, California, United States, 90048
3
Stanford
Stanford, California, United States, 94305
4
Yale New Haven Hospital
New Haven, Connecticut, United States, 06510